AI drug discovery company
Latent Labs
Data as of .
Company facts
-
Founded
2023
-
Headquarters
United Kingdom (London)
-
Total funding
$50M
Latest funding round
- Round
- Series A
- Date
- Feb 12, 2025
- Amount
- $40M
- Lead investor
- Radical Ventures and Sofinnova Partners (co-leads)
Recent news
-
At SynBioBeta, says Latent-X2 antibodies were developable 47% of the time without optimization
-
Launches Latent-Y, which it calls a general drug design AI
-
Announces Latent-X2, AI-generated antibodies with drug-like developability
-
Launched web-based AI protein design model
-
Series A: $40M
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.